---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-23-000134"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2023-08-29T23:59:59+00:00"
generated_at: "2026-06-11T02:24:41.707898+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BeiGene reports H1 2023 R&D expenses of $831M; breakdown by key pipeline assets

## Summary
- Total R&D expenses for H1 2023 were $831.3M, up from $768.1M in H1 2022.
- Zanubrutinib R&D: $81.1M (H1 2023) vs $71.0M (H1 2022).
- Tislelizumab R&D: $47.0M; Ociperlimab: $38.8M; Pamiparib: $4.4M.
- Bcl-2 (BGB-11417) R&D: $17.5M; OX40 (BGB-A445): $8.9M; other projects: $60.6M.
- Differences between PRC GAAP and US GAAP summarized, mainly share-based comp and leasing treatment.

## SEC filing metadata
- accession: 0001651308-23-000134
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2023-08-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000134/0001651308-23-000134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000134/bgne-20230829.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-23-000134
- JSON: https://secwatch.observer/filing/0001651308-23-000134.json
- Plain text: https://secwatch.observer/filing/0001651308-23-000134.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.